Consult trial design [Design Issues]

posted by libaiyi – China, 2024-07-03 11:12 (14 d 17:32 ago) – Posting: # 24058
Views: 345

Hello everyone, I have two questions. The first question is that I would like to know if ANDA only includes BE studies, and if the endpoints for BE studies can be efficacy endpoints instead of PK parameters.

The second question is about a pediatric anesthetic drug that we have applied NDA in China, and we now want to apply NDA in Europe and the United States. The drug has already been approved for use in adults in Europe and the United States. Can we apply for market approval with just a pediatric bridging study, or we need to collect data from both adults and a small number of children in Europe and the United States and conduct a regular study design? Is there any reference study or paper available?

Thank you very much!

Complete thread:

UA Flag
 Admin contact
23,107 posts in 4,858 threads, 1,644 registered users;
67 visitors (0 registered, 67 guests [including 8 identified bots]).
Forum time: 04:45 CEST (Europe/Vienna)

All paid jobs absorb and degrade the mind.    Aristotle

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz